Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00482352 · ClinicalTrials.gov registry record
Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
A clinical trial, sponsored by Children's Oncology Group.
- Completed
- Registry status
- 11,196
- Enrollment target
NCT00482352: Completed study, sponsored by Children's Oncology Group.
NCT00482352 is a clinical trial that has completed, run by Children's Oncology Group. The registered enrollment target is 11,196 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00482352 has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- 11,196 participants
- Enrollment target
Study Summary
This clinical trial is studying risk-group classification of patients with newly diagnosed acute lymphoblastic leukemia. Developing a risk-group classification guide may help doctors assign patients with newly diagnosed acute lymphoblastic leukemia to treatment clinical trials.
Interventions
- OTHER laboratory biomarker analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,196 participants |
| Start Date | 2003-12 |
| Est. Completion | 2023-06-30 |
What the finished NCT00482352 record still lists
NCT00482352 is an observational study that tracks outcomes without assigning an intervention. Its 11,196 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which laboratory biomarker analysis is the first listed.
NCT00482352 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00482352 about?
NCT00482352 is a clinical study titled "Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia". This clinical trial is studying risk-group classification of patients with newly diagnosed acute lymphoblastic leukemia. Developing a risk-group classification guide may help doctors assign patients with newly diagnosed acute lymphoblastic leukemia to treatment clinical trials.
What is the current status of trial NCT00482352?
This trial is currently completed. The enrollment target is 11,196 participants. The study started on 2003-12. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT00482352?
The interventions under investigation include: laboratory biomarker analysis (OTHER).
Who is sponsoring clinical trial NCT00482352?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06677060 · 11,300 participants · Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- NCT07181109 · 11,000 participants · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia